Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know

13.04.24 00:00 Uhr

Werte in diesem Artikel
Aktien

62,43 EUR 0,28 EUR 0,45%

Indizes

PKT PKT

18.674,2 PKT 128,0 PKT 0,69%

16.794,9 PKT 108,9 PKT 0,65%

2.525,7 PKT 3,1 PKT 0,12%

1.854,4 PKT -8,4 PKT -0,45%

5.308,1 PKT 4,9 PKT 0,09%

The most recent trading session ended with Gilead Sciences (GILD) standing at $68.07, reflecting a -0.84% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily loss of 1.46%. On the other hand, the Dow registered a loss of 1.24%, and the technology-centric Nasdaq decreased by 1.63%.The HIV and hepatitis C drugmaker's stock has dropped by 7.49% in the past month, falling short of the Medical sector's loss of 4.66% and the S&P 500's gain of 1.6%.The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company is slated to reveal its earnings on April 25, 2024. In that report, analysts expect Gilead Sciences to post earnings of $1.59 per share. This would mark year-over-year growth of 16.06%. Our most recent consensus estimate is calling for quarterly revenue of $6.33 billion, down 0.41% from the year-ago period.For the full year, the Zacks Consensus Estimates project earnings of $7.08 per share and a revenue of $27.48 billion, demonstrating changes of +5.36% and +1.33%, respectively, from the preceding year.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.13% higher. As of now, Gilead Sciences holds a Zacks Rank of #3 (Hold).Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 9.7. This indicates a discount in contrast to its industry's Forward P/E of 22.04.Meanwhile, GILD's PEG ratio is currently 0.87. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.9 at yesterday's closing price.The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 83, finds itself in the top 33% echelons of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Highest Returns for Any Asset ClassIt’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.Hurry, Download Special Report – It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Gilead Sciences

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Gilead Sciences

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Gilead Sciences Inc.

Analysen zu Gilead Sciences Inc.

DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
26.07.2018Gilead Sciences NeutralRobert W. Baird & Co. Incorporated
05.10.2017Gilead Sciences PerformOppenheimer & Co. Inc.
09.03.2017Gilead Sciences NeutralUBS AG
29.04.2016Gilead Sciences HoldMaxim Group
14.12.2012Gilead Sciences neutralGoldman Sachs Group Inc.
DatumRatingAnalyst
25.06.2010Gilead Sciences ausgestopptDer Aktionär
22.10.2009Gilead Sciences underperformWedbush Morgan Securities Inc.
10.02.2006Gilead Sciences underweightPrudential Financial
06.12.2005Gilead Sciences underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Gilead Sciences Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"